ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 15 of 60 for:    "hyperparathyroidism-jaw tumor syndrome" OR "Primary Hyperparathyroidism" OR "Hyperparathyroidism, Primary"

Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Trial (SIPH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00522028
Recruitment Status : Completed
First Posted : August 29, 2007
Last Update Posted : May 23, 2016
Sponsor:
Collaborators:
Rikshospitalet University Hospital
Göteborg University
Rigshospitalet, Denmark
Karolinska University Hospital
Uppsala University Hospital
Haukeland University Hospital
St. Olavs Hospital
Information provided by (Responsible Party):
Jens Bollerslev, Oslo University Hospital

Brief Summary:
The present study is a randomized, controlled trial that investigates the effects of parathyroidectomy or medical observation in mild asymptomatic pHPT on morbidity and quality of life (QoL).

Condition or disease
Primary Hyperparathyroidism

Detailed Description:

The patients are included and randomized by block randomization to medical observation or parathyroidectomy by an experienced parathyroid surgeon.

The patients will be followed up for 10 years.


Study Type : Observational
Actual Enrollment : 191 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Trial
Study Start Date : October 1998
Actual Primary Completion Date : January 2016
Actual Study Completion Date : January 2016






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Primary care clinic
Criteria

Inclusion Criteria:

  • Untreated, asymptomatic pHPT
  • 2.60>S-Ca<2.85 mmol/liter
  • Age between 50 and 80 yr
  • No medications interfering with Ca-metabolism
  • Informed consent

Exclusion Criteria:

  • Hyperparathyroid bone disease
  • Previous operation in the neck
  • Impaired kidney function
  • Kidney stones
  • Complicating medical conditions
  • Psychiatric disorders
  • Multiple endocrine neoplasia,
  • Familial hypocalcuric hypercalcemia
  • Familial HPT

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00522028


Locations
Norway
Oslo University Hospital - Rikshospitalet
Oslo, Norway, 0027
Sponsors and Collaborators
Oslo University Hospital
Rikshospitalet University Hospital
Göteborg University
Rigshospitalet, Denmark
Karolinska University Hospital
Uppsala University Hospital
Haukeland University Hospital
St. Olavs Hospital
Investigators
Principal Investigator: Jens Bollerslev, MD Rikshospitalet University Hospital

Publications of Results:
Responsible Party: Jens Bollerslev, Professor, Oslo University Hospital
ClinicalTrials.gov Identifier: NCT00522028     History of Changes
Other Study ID Numbers: S-96107 (REK)
9571 (NSD) ( Other Identifier: Oslo University Hospital )
First Posted: August 29, 2007    Key Record Dates
Last Update Posted: May 23, 2016
Last Verified: June 1996

Keywords provided by Jens Bollerslev, Oslo University Hospital:
QoL
Osteodensitometry
Arterial pressure
PTH

Additional relevant MeSH terms:
Hyperparathyroidism
Hyperparathyroidism, Primary
Parathyroid Diseases
Endocrine System Diseases